Slide 1: Investor Conference Call Q1 2021 Results
Investor Conference Call /////////// Q1 2021 Results May 12, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO RESTRICTED
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Q1 2021 Results: Business Update
Q1 2021 Results Business Update /////////// Werner Baumann, CEO
Slide 4: Successful Start into the Year
Successful Start into the Year 1 Solid cpa sales growth driven by Crop Science 2 Currency headwinds mask underlying performance 3 Finerenone meets primary endpoint in Phase III FIGARO-DKD trial 4 Bayer Q1 2021 Investor Conference Call
Slide 5: Q1 2021 Results: Business Performance & Outlook
Q1 2021 Results Business Performance & Outlook /////////// Wolfgang Nickl, CFO
Slide 6: Good Underlying Momentum Masked by Currency Headwinds
Good Underlying Momentum Masked by Currency Headwinds Sales EBITDA Core EPS Free Cash Flow In million €, ∆% yoy In million €, before special items In €, Cont. Operations In million € - 4% (+3% cpa) 12,845 12,328 -6% 4,391 4,118 -3% 2.67 -793 2.59 34.2% 33.4% -3,226 Q1'20 Q1'21 Q1'20 Q1'21 Q1'20 Q1'2
Slide 7: Crop Science Off to a Strong Start
Crop Science Off to a Strong Start Sales Sales EBITDA Key Messages InIn million €,€, million ∆% yoy, ∆% yoycpa. In million €, before special items • Positive market sentiment due to high - 3% commodity prices for corn and soy Volume (+6% cpa) +5% • Soybean Seed & Traits sales with +3% 6,834 6,646 ma
Slide 8: Pharma on Track for Sustained Growth Momentum
Pharma on Track for Sustained Growth Momentum Sales Sales EBITDA Key Messages InIn million €,€, million ∆% yoy, ∆% yoycpa. In million €, before special items • Good performance of Eylea (+16%) and - 4% Xarelto (+7%) Volume (0% cpa) +4% • Good growth momentum for elective 4,546 4,365 treatments: IUD
Slide 9: Consumer Health Continues Outperformance
Consumer Health Continues Outperformance Sales Sales EBITDA Key Messages InIn million €,€, million ∆% yoy, ∆% yoycpa. In million €, before special items • Despite challenging Q1 environment, we - 10% continue to outperform the market while Volume cycling over record prior-year quarter (-4% cpa) -8%
Slide 10: We Confirm our Outlook for 2021 (as Shown in February)
We Confirm our Outlook for 2021 (as Shown in February) At constant currencies1 Expected currency impact² Sales €42bn - €43bn ~ -€2bn EBITDA margin ~ 27% ~ -70bps (before special items) Core EPS €6.10 – €6.30 ~ -€50ct Free Cash Flow ~ -€3bn - -€4bn3 No major impact Net financial debt ~ €36bn - €37bn
Slide 11: Investor Conference Call Q1 2021 Results
Investor Conference Call /////////// Q1 2021 Results May 12, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO RESTRICTED
Slide 12: Q1 2021: Key KPIs Bayer Group
Q1 2021: Key KPIs Bayer Group Q1 2020 Q1 2021 Net Sales 12,845 12,328 EBITDA before special items 4,391 4,118 Special items -615 51 1 Reported EBITDA 3,776 4,169 Depreciation & Amortization -1,277 -1,086 Reported EBIT 2,499 3,083 • Positive impact from income of Jivi patent Amortization and impairme
Slide 13: Q1 2021: Key KPIs by Division
Q1 2021: Key KPIs by Division Crop Science Pharmaceuticals Consumer Health Reconciliation Group [€ million] Q1'20 Q1'21 Q1'20 Q1'21 Q1'20 Q1'21 Q1'20 Q1'21 Q1'20 Q1'21 Sales 6,834 6,646 4,546 4,365 1,398 1,252 67 65 12,845 12,328 Sales by region: Europe / Middle East / Africa 1,894 1,881 1,799 1,695
Slide 14: Core EPS to EPS bridge
Core EPS to EPS bridge in € -0.73 0.18 0.04 0.05 2.59 2.13 Core EPS Depreciation & Special items Special items Tax effect EPS (total) Q1'2021 Amortization (EBITDA) financial result/ on adjustments Q1'2021 (on IP & PPE) taxes 14 Bayer Q1 2021 Investor Conference Call
Slide 15: Unmatched Innovation Pipeline is Set to Drive Growth
Unmatched Innovation Pipeline is Set to Drive Growth (as of March 2021) Total Pipeline Peak Sales Potential up to €30bn2; ~50% Incremental Other, Vegetable Seeds, Corn S&T Soybean S&T Herbicides Fungicides Insecticides Environmental Science Peak Sales Potential ~€10-11bn ~€4-5bn ~€3bn ~€3bn ~€2bn ~€
Slide 16: Pharmaceuticals Division: Overview Development Portfolio
Pharmaceuticals Division: Overview Development Portfolio (as of May 2021) Phase I (25) Phase II (20) Phase III (8) Selitrectinib (TRK Inhibitor, formerly LOXO-195) Urothelial Cancer /// Rogaratinib (pan-FGFR Inhibitor) Prostate Cancer (mHSPC) /// Darolutamide (AR Inhibitor) Rogaratinib (pan-FGFR Inh
Slide 17: 2021: Divisional Guidance (as Shown in February)
2021: Divisional Guidance (as Shown in February) Guidance at constant currencies Sales Growth EBITDA-margin EBITDA-margin Est. Market Division Sales 2020 Growth 2021 2021 2020 2021 (cpa) (before special items) (before special items) Crop €18.8bn ~ 2% ~ 2% 24.1% ~ 24% Science Pharma €17.2bn ~ 5% ~ 4%
Slide 18: 2021: Guidance for Other Group KPIs (as Shown in February)
2021: Guidance for Other Group KPIs (as Shown in February) Guidance at constant currencies* Special items (EBITDA) • ~ €1.5 bn Depreciation and amortization (clean) • ~ €4.2 bn of which for intangible assets (clean) • ~ €2.3 bn Core financial result • ~ -€1.6 bn Core tax rate • ~ 23% Reconciliation
Slide 19: Investor Conference Call Q1 2021 Results
Investor Conference Call /////////// Q1 2021 Results May 12, 2021 Werner Baumann, CEO Wolfgang Nickl, CFO RESTRICTED